The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Freezing of Gait Program, 2024Using Adaptive Cortical Neuromodulation to Treat Freezing of Gait in Parkinson’s Disease
Study Rationale: Difficulties with walking can significantly impact the quality of life for people with Parkinson’s disease (PD). One of the most serious issues is freezing of gait (FOG), episodes in...
-
Parkinson’s Disease Therapeutics Pipeline Program, 2024Development of a First-in-class Inhibitor of the “Mitochondrial Permeability Transition Pore” as a Novel Disease-modifying Treatment for Parkinson’s Disease
Study Rationale: Mitochondria are subcellular structures that produce energy and help regulate the movement of calcium ions that continually flow into brain cells when they are active, ions that can...
-
Research Grant, 2024Measurement of Phosphorylated Alpha-synuclein in Skin Biopsies as a Prospective Biomarker for Parkinson’s Disease
Study Rationale: Parkinson’s disease (PD) is associated with an accumulation of phosphorylated alpha-synuclein, and the amount of the protein increases as PD progresses. We have found that we can...
-
Research Grant, 2024Developing Community Health Worker Remote Training Modules on Research, Brain Health and Parkinson’s Disease
Study Rationale: Neurodegenerative diseases including Parkinson's disease (PD) disproportionately impact underserved communities due to barriers in research participation and awareness. Community...
-
Parkinson’s Disease Therapeutics Pipeline Program, 2024Development of Novel LRRK2 Inhibitors for the Treatment of Parkinson’s Disease
Study Rationale: Inhibitors of the LRRK2 protein offer promise as a therapy for Parkinson’s disease (PD). The leading inhibitors currently under development, the so-called Type 1 kinase inhibitors...
-
Research Grant, 2024Assessment of Longitudinal Imaging Using Radiolabeled AV-133 in Early and Prodromal Parkinson’s Disease
Study Rationale: The clinical phase of Parkinson’s disease (PD) is preceded by a prodromal phase of progressing neurodegeneration that can last many years. Imaging markers such as radiolabeled AV-133...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.